# Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

> **NCT05519410** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Resectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sintilimab and Lenvatinib
- **DRUG:** HAIC-FOLFOX

## Key facts

- **NCT ID:** NCT05519410
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-23
- **Primary completion:** 2024-09-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05519410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05519410, "Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05519410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*